A modern approach to developing specifications for a generic drug used to treat aromatic amino acid metabolism disorders

Abstract

Inherited disorders of aromatic amino acid metabolism, particularly hereditary tyrosinemia type I, are severe genetic diseases requiring lifelong dietary and pharmacological management. Specialized amino acid mixtures free of tyrosine represent the cornerstone of therapy, as they provide essential amino acids while preventing the accumulation of toxic metabolites.